Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Increases speed to market for drug developers working on nucleic acid therapeutics
Subscribe To Our Newsletter & Stay Updated